NCT01003301View on ClinicalTrials.gov

The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

September 30, 2013

Conditions
Cat Allergy
Interventions
DRUG

Omalizumab

Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.

DRUG

Placebo

Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.

Trial Locations (1)

21224

Johns Hopkins Asthma and Allergy Center, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER